Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients

Table 4

BMI-based subgroup analysis of biochemical and BMD characteristics in the olanzapine-treated group ().

	Normal weight ()	Overweight ()	Obesity ()		Multicomparison
TG (mmol/L)				0.030
CHOL (mmol/L)				0.241	—
HDL (mmol/L)				0.162	—
LDL (mmol/L)				0.851	—
FBG (mmol/L)				0.001	No,
Insulin (μU/mL)				0.041
BMD, radius+ulna (g/cm^2)
1/3				0.718	—
MID				0.518	—
UD				0.373	—
TOTAL				0.583	—
BMD, lumbar (g/cm^2)
L1				<0.001	No,
L2				0.001	No,
L3				0.009
L4				0.818	—
L1-4				0.808	—
BMD, left hip (g/cm^2)
NECK				0.004	No,
TROCH				0.003	No,
WARD				0.019
T-HIP				<0.001

Comparison of biochemical and BMD characteristics among the normal weight, overweight, and obesity subgroups.